 |
The drug development space is evolving — and the trends in outsourcing models are changing to meet new demands. In just three years, usage of functional service provider (FSP) models went from 28% to 41% — and hybrid FSP/full-service outsourcing (FSO) models now represent two-thirds of arrangements. Join subject matter expert Edel Shaw, Director of PPD FSP Solutions, in our latest webinar to explore the recent shift to FSP outsourcing, the use of FSP outsourcing by drug development companies, and key considerations when selecting an FSP provider. Watch now to learn more about:
|
